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Squamoid Eccrine Ductal Carcinoma
of the Eyelid: Clinicopathologic
Correlation of a Case
Nish Patel, M.D.*, Chrisfouad R. Alabiad, M.D.†,
Mark R. Wick, M.D.‡, George W. Elgart, M.D.§,
Vincent D. Tang, B.S.†║, Rayan A. Abou Khzam, M.D.†║,
and Sander R. Dubovy, M.D.†║
Abstract: Squamoid eccrine ductal carcinoma (SEDC) is a
rare cutaneous neoplasm that often manifests as a plaque
or nodule in sun-exposed areas of older patients. Herein,
the authors report the first case of SEDC in the eyelid. A
76-year-old man presented with a 2.5 × 1.5 mm area of left
upper eyelid erythema, thickening, ulceration, and scaling
with madarosis superotemporally just above the lash line.
Full-thickness wedge biopsy demonstrated irregular epithelial tubules with nuclear atypia and focal squamous differentiation, consistent with SEDC. The patient underwent
Mohs resection and has had no recurrence approximately
27 months after surgical removal. The authors present this
case to raise awareness of SEDC to ophthalmologists as all
previous cases have been described in the nonophthalmic
literature. A full-thickness biopsy is recommended to avoid
misdiagnosing SEDC as squamous cell carcinoma (SCC),
a less aggressive tumor. With greater awareness, there may
be increased recognition of this likely underreported, more
malignant entity.

S

kin adnexal carcinomas are rare, with a reported incidence
of 5.1 per 1 million person-years in a recent populationbased study.1 Eccrine carcinoma, a subset of adnexal malignancies that originate from the eccrine glands, is the most
common form of adnexal carcinoma and represents <0.01%
of all cutaneous tumors.2 Accurate diagnoses of these lesions
can be difficult given both their rarity and histologic variability.3 Furthermore, the histopathology of these entities can
resemble metastatic carcinoma from sites such as the breast,
lung, and kidney.4
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FIG. 1. Clinical photograph after initial incisional biopsy but
before wedge resection: A 2.5 × 1.5 mm area of erythema, thickening, ulceration, and scaling with madarosis is present in the superotemporal region of the left upper eyelid just above the lash line.

In the eyelid, 3 distinct subtypes of eccrine carcinoma
have been identified: mucinous, adenoid, and ductal.5 Ductal
eccrine carcinoma is the most common subtype and often manifests in middle-aged to older patients as a plaque or nodule on
the scalp, trunk, or extremities.2 Although less commonly identified in the eyelid, a number of cases of ductal eccrine carcinoma have been reported to occur in this area.6,7
A variation of ductal eccrine carcinoma that features
prominent squamous differentiation, termed squamoid ductal
eccrine carcinoma (SEDC), was first described in a series of
3 cases in 1997.8 Over the course of almost 20 years, less than
a dozen subsequent cases of this entity were reported, many
in the form of case reports or small case series.9,10 In 2016, a
clinicopathologic study of 30 cases was published and showed
that SEDC typically manifests as ulcerated nodules and plaques
in sun-exposed areas, primarily the face, in the seventh and
eighth decades of life. Histologically, these tumors demonstrate
a biphasic appearance. The superficial component displays
squamous differentiation with epidermal connection, often in a
background of actinic keratosis or SCC in situ. The deeper component is characterized by infiltration of cords and strands in a
desmoplastic stroma with cellular atypia and varying amounts
of duct differentiation.11 To date, there has been no published
reports of SEDC in the eyelid. Here, the authors present a case
of SEDC in the upper eyelid of a 76-year-old man with upper
eyelid thickening, ulceration, and madarosis. Of note, the study
adhered to HIPAA standards and tenets of the Declaration of
Helsinki in the collection and analysis of this patient’s protected
health information.

CASE PRESENTATION
A 76-year-old Caucasian male was referred to oculoplastics clinic for a left upper eyelid lesion. The patient had been
treated with tetracycline ointment for 2 weeks. Past ocular history included central retinal vein occlusion with cystoid macular
edema in the left eye (treated with intravitreal aflibercept) and
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FIG. 2. Histopathology of the eyelid lesion. A, Irregular epithelial tubules with nuclear atypia are present in the deeper dermis along
with squamous differentiation present superficially (Hematoxylin-eosin, original magnification ×40). B, The deeper dermis consists of
infiltrative tubules in a desmoplastic stroma with perineural invasion (Hematoxylin-eosin, original magnification ×200). C, The superficial portion of the tumor demonstrates focal squamous differentiation with connection to the epidermis (Hematoxylin-eosin, original
magnification ×200). D, The squamous and ductal portions of the tumor stain positively for pan cytokeratin (Leica) (Pan cytokeratin,
original magnification ×100). E, The ductal component of the tumor stains positively for CEA (Leica, Agilent Dako), while the squamous portion does not stain for CEA (Carcinoembryonic antigen, original magnification ×100). F, Perineural involvement of carcinoma
(arrow) is present adjacent to the otherwise unremarkable peripheral nerve (asterisk). G, The S-100 stain (Leica) highlights the peripheral nerve (asterisk) and the perineural involvement of carcinoma (arrow).

cataracts in both eyes. Relevant medical history included significant sun exposure with several nonmelanomatous skin cancers
of the face including SCCs of the right naris and right nasal ala
skin and basal cell carcinoma of the scalp. On initial examination, the patient’s visual acuity, with pinhole, was 20/40 in
both eyes. Blepharitis (3+) as well as upper and lower lid laxity
were noted bilaterally with no evidence of an eyelid lesion. The
patient was managed conservatively with warm compresses,
eyelid scrubs, and neomycin/polymyxin B/dexamethasone ointment. Follow-up examination 7 months later revealed similar
findings but additionally noted 2 left upper eyelid excoriated
lesions accompanied by madarosis, loss of eyelid architecture,
and telangiectasias. The patient underwent excisional biopsy of
these lesions. Histopathology demonstrated hyperkeratotic and
parakeratotic material with acute and chronic inflammation and
Gram positive cocci. The patient continued to be managed conservatively and improvement in the patient’s eyelid lesions was
observed.
Approximately 2 years after the initial biopsy, the patient
was noted to have developed a 2.5 × 1.5 mm area of erythema, thickening, ulceration, and scaling with madarosis in
the superotemporal region of the left upper eyelid just above
the lash line. Repeat biopsy with pentagonal wedge resection
was performed at this time given the concern for malignancy.
A clinical photograph of the patient’s eyelid after initial incisional biopsy but before wedge resection is shown in Figure 1.
Histopathology demonstrated irregular epithelial tubules with
nuclear atypia as well as focal squamous differentiation present superficially (Fig. 2A, C). Both the squamous and ductal
portions of the tumor stained positively for pan cytokeratin
(Leica). The eccrine ductal component stained positively for
carcinoembryonic antigen (CEA; Leica, Agilent Dako) while

the squamous component did not stain for CEA (Fig. 2D, E).
The squamous component of the lesion variably stained positively for CK7 (Leica), p63 (Biocare), and CK5/6 (Leica), while
the ductal component stained positively for EMA (Cell marque)
and CD15 (Leica) (stains not shown). The lesion did not stain
for CK20 (Leica) or GCFDP-15 (Leica) (stains not shown).
Finally, the tumor demonstrated perineural invasion (Fig. 2F,
G). The morphologic and immunohistochemical features of this
lesion were consistent with a ductal eccrine adenocarcinoma
with focal squamous differentiation.
A PET/CT scan performed 2 months later displayed no
clear evidence of metastases. The patient subsequently underwent Mohs resection with reconstruction. After 2 stages of
Mohs surgery, the patient’s eyelid was free of tumor. At the
patient’s most recent follow-up visit, approximately 27 months
after the wedge resection was performed, the patient presented
with no evidence of recurrence, infection, or issues with graft
perfusion.

DISCUSSION
SEDC is a very rare entity, and herein, the authors report
the first case of this tumor in the eyelid. The presence of this
lesion in an individual in the eighth decade of life with a history of evident sun exposure to the face is consistent with that
of prior studies.6,11 Immunosuppression has been suggested as
a potential risk factor not only because of the association with
older age but also due to the fact that several cases of SEDC
have been reported in patients with a history of chronic lymphocytic leukemia or immunosuppression after organ transplant.3,6 The patient in this study had no history of hematologic
malignancy or immunosuppressive medication use. Though the
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typical presentation of these lesions include the presence of a
nodule, papule, or plaque,3,6,9–12 there are cases where an ulcerated lesions were described.6,11
Histopathology of the case is consistent with that of prior
cases of SEDC: the presence of focal squamous differentiation
predominately in the epidermis and superficial dermis combined
with the growth of ducts and strands in the deeper dermis.6,11
The immunohistochemical profile is also consistent with that of
several prior studies.11,12 Furthermore, cytologic atypia and perineural invasion are noted in this case. In the largest published
series of SEDC (30 cases), these tumors displayed moderate-tosevere atypia, and 27% featured perineural invasion.11
The differential diagnosis of this lesion includes SCC,
metastatic carcinoma with squamoid features, and other adnexal
eccrine carcinomas including microcystic adnexal carcinoma,
porocarcinoma with squamous differentiation, and syringoid
eccrine carcinoma. Histologically, porocarcinomas may display squamous differentiation but do not typically demonstrate
the biphasic pattern seen in SEDC.12 Microcystic adnexal carcinomas also can exhibit squamoid features but are additionally characterized by keratinous cysts, which are not seen in
SEDC.9,12 Although syringoid eccrine carcinomas are similar to
SEDC in that they display a deep infiltrative growth pattern of
ducts, they lack squamous differentiation.11,12 Metastatic carcinoma can be ruled out with the use of immunohistochemistry,
namely p63 and CK5/6, whose positivity confirms the primary
cutaneous nature of the malignancy.3,10,12
The distinction between SEDC and SCC deserves special
attention as SEDC can easily be mistaken for SCC. These misdiagnoses have at least, in part, resulted from the use of superficial diagnostic biopsies such as shave or scoop biopsies. These
techniques permit examination of only the superficial aspects
of the tumor, often resulting in a diagnosis of SCC.9,12 Such
instances highlight the importance of performing an excisional
or full-thickness incisional biopsy in situations where an eccrine
ductal carcinoma is possible in order not to miss the ductal differentiation that typically predominates in the deeper portions
of this tumor. Furthermore, issues with misdiagnosis imply that
SEDC is likely an underdiagnosed and underreported entity.
Since only a small number of cases of SEDC have been
reported, there is limited information on how to specifically
manage this malignancy. The general consensus is similar to
that of SCC treatment in that wide surgical excision should
be performed with clear margins, with or without Mohs surgery.2,3,9,10 While these lesions are managed similarly, the prognoses are different. Local recurrence rates for SEDC have been
reported to be as high as 70%–80% compared to SCC, which
has reported recurrence rates of 3.1%–18.7%.3 Similarly, metastasis rates for SEDC (up to 50%) are much higher than those
for SCC (0.5%).2 This case study demonstrated no evidence of
recurrence approximately 27 months after wedge resection. In
the series of 30 cases published by van der Horst et al.,11 25% of
patients with available follow-up information had local recurrences with a median time to recurrence of 14 months. Thirteen
percent of patients at follow-up had regional lymph node metastases with one patient dying of metastases 32 months after the
diagnosis.11 Based on this data, close follow-up with surveillance is recommended for cases of SEDC. Since this is the first
time SEDC has been identified in the eyelid, it is not clear to
what extent current treatment recommendations and prognosis
data for this tumor apply to this scenario.
In summary, the authors present the first case of SEDC
in the eyelid with the goal of raising awareness of this entity to
ophthalmologists as all previous cases have been described in
the dermatology and pathology literature. Our case features a
76-year-old man with left upper eyelid superotemporal thickening
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with irritation, madarosis, and ulceration. A pentagonal wedge
resection was performed, and histopathology demonstrated
growth of epithelial tubules in the dermis with nuclear atypia and
focal squamous differentiation, consistent with SEDC. This study
emphasizes the importance of performing a full-thickness anterior lamellar biopsy or a full-thickness eyelid biopsy when eccrine
ductal carcinomas are on the differential to avoid misdiagnosis of
these lesions as SCC, an entity with less aggressive behavior. As
clinicians become increasingly aware of SEDC, these tumors are
likely to be diagnosed more often, providing with more information on how to effectively manage these lesions.
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Bilateral Enophthalmos as an Unusual
Presenting Feature of Non-Hodgkin’s
Orbital Lymphoma
Micheal A. O’Rourke, M.B., F.R.C.S.I.(OPHTH.), F.E.B.O.,
PH.D.,*
Penelope A. McKelvie, M.B.B.S., D.MED.SC., F.R.C.P.A.,†
Thomas G. Hardy, M.B.B.S., F.R.A.N.Z.C.O.,*
and Alan A. McNab, M.B.B.S., D.MED.SC., F.R.A.N.Z.C.O.,
F.R.C.OPHTH.*
Abstract: Lymphoma is the commonest orbital malignancy. The typical presentation is proptosis or swelling,
which warrants imaging and confirmation by tissue biopsy.
Enophthalmos is a much rarer clinical sign and if bilateral and symmetrical can often present late. We describe
a patient who presented with bilateral enophthalmos and
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